ethyl 1-benzyl-5-chloroindole-2-carboxylate | 95306-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 1-benzyl-5-chloroindole-2-carboxylate
• 英文别名: Ethyl 5-chloro-1-(phenylmethyl)-1H-indole-2-carboxylate；1-benzyl-5-chloroindole-2-carboxylic acid ethyl ester
• CAS: 95306-84-6
• 化学式: C₁₈H₁₆ClNO₂
• 分子量: 313.784
• InChiKey: RIOJHKOPSLXMTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 1-benzyl-5-chloroindole-2-carboxylate 在 水 、 potassium hydroxide 作用下， 以 乙醇 为溶剂， 生成 5-氯-1-苄基吲哚-2-羧酸
  参考文献：
  名称：

  The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists

  摘要：

  The discovery and structure-activity relationship of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB1 receptor is disclosed. Compound 26i was found to be a high potency, selective cannabinoid CB1 antagonist. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.104
• 作为产物：
  描述：

  溴甲苯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.33h， 生成 ethyl 1-benzyl-5-chloroindole-2-carboxylate
  参考文献：
  名称：

  Acyl indoles, compositions containing such compounds and methods of use

  摘要：

  本发明涉及替代吲哚类化合物，含有这种化合物的组合物，以及治疗方法。这些化合物是胰高血糖素受体拮抗剂，因此可用于治疗、预防或延缓2型糖尿病及相关疾病的发生。

  公开号：

  US20070088071A1

文献信息

• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• A New Class of Amide Ligands Enable Cu-Catalyzed Coupling of Sodium Methanesulfinate with (Hetero)aryl Chlorides
  作者：Dawei Ma、Songtao Niu、Jinlong Zhao、Xi Jiang、Yongwen Jiang、Xiaojing Zhang、Tiemin Sun

  DOI：10.1002/cjoc.201700477

  日期：2017.11

  ((2S,4R)‐4‐Hydroxy‐N‐(2‐methylnaphthalen‐1‐yl)pyrrolidine‐2‐carboxamide (HMNPC), an amide derived from 4‐hydroxy‐L‐proline and 2‐methyl naphthalen‐1‐amine, is a powerful ligand for Cu‐catalyzed coupling of (hetero)aryl halides with sulfinic acid salts, allowing for first time the metal‐catalyzed coupling of (hetero)aryl chlorides and NaSO2Me. A considerable number of (hetero)aryl chlorides worked well

  （（2 S，4 R）-4-羟基N-（2-甲基萘-1-基）吡咯烷-2-羧酰胺（HMNPC），一种由4-羟基-L脯氨酸和2-甲基萘衍生的酰胺1-胺是（杂）芳基卤化物与亚磺酸盐的Cu催化偶联的强配体，首次使（杂）芳基氯化物与NaSO 2 Me发生金属催化偶联。 ）芳基氯化物的效果很好，以良好的收率提供了药学上重要的（杂）芳基甲基砜。
• Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: Exploration of 5–6 fused rings as alternative S1 moieties
  作者：Kenji Yoshikawa、Aki Yokomizo、Hiroyuki Naito、Noriyasu Haginoya、Shozo Kobayashi、Toshiharu Yoshino、Tsutomu Nagata、Akiyoshi Mochizuki、Ken Osanai、Kengo Watanabe

  DOI：10.1016/j.bmc.2009.10.023

  日期：2009.12.15

  A series of cis-1,2-diaminocyclohexane derivatives were synthesized with the aim of optimizing previously disclosed factor Xa (fXa) inhibitors. The exploration of 5–6 fused rings as alternative S1 moieties resulted in two compounds which demonstrated improved solubility and reduced food effect compared to the clinical candidate, compound A. Herein, we describe the synthesis and structure–activity relationship

  为了优化先前公开的因子Xa（fXa）抑制剂，合成了一系列顺式-1,2-二氨基环己烷衍生物。探索5-6个稠合环作为S1的替代部分，与临床候选化合物A相比，发现了两种化合物具有更高的溶解度和降低的食物效果。在这里，我们描述了一些预期化合物的合成和结构-活性关系（SAR），以及理化性质和药代动力学（PK）谱。
• Diversity-Oriented Synthesis of Calothrixins and Ellipticines
  作者：Dattatraya H. Dethe、Ganesh M. Murhade

  DOI：10.1002/ejoc.201402837

  日期：2014.11

  The divergent synthesis of calothrixins and ellipticines has been accomplished by utilising the one-pot formation of o-diacylarenes as a key intermediate through rearrangement of o-hydroxy ketone monoacyl hydrazones by lead tetraacetate mediated oxidation.

  通过四乙酸铅介导的氧化重排邻羟基酮单酰基腙，利用邻二酰基芳烃作为关键中间体的一锅形成，完成了calothrixins和玫瑰树碱的不同合成。
• Diamine Derivatives
  申请人：Ohta Toshiharu

  公开号：US20110312990A1

  公开（公告）日：2011-12-22

  A compound represented by the general formula (1): -Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  化合物的一般式表示为(1)：-Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4(1)，其中R1和R2为氢原子或类似物；Q1为饱和或不饱和的5-或6-成员环烃基，可以是取代基或类似物；Q2为单键或类似物；Q3为其中Q5为1至8个碳原子的烷基或类似物的基团；T0和T1为羰基或类似物。该化合物及其盐、溶剂化物或N-氧化物可用于预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)、体外循环期间的血栓形成或采血时的血液凝固。